A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-
Expansion Study to Evaluate the Safety, Pharmacokinetics,
Pharmacodynamics, and Antitumor Activity of AO-176
The purpose of this study is to find out if the investigational drug called AO-176 is safe in people with a variety of different cancers and what effects it has on cancer.
epithelial ovarian carcinoma
squamous cell carcinoma of the head and neck
castration resistant prostate cancer
non-small cell lung adenocarcinoma
papillary thyroid cancer
gastric adenocarcinoma (and gastro-esophageal junction adenocarcinoma)
Male and Female participants of 18 years of age and older.
Diagnosed with cancer mentioned in the previous list.
18 - 100
Healthy Volunteers Needed
Duration of Participation
The study is planned to last for about 2 ½ years. How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.
If your cancer improves or stays the same and you do not have serious side effects from the study drug, you may remain in the study as long as your study doctor feels you may benefit from AO-176. However, you are free to stop taking part in this study at any time and for any reason.
Knight Clinical Trials Information Line